Radionuclide News and Research

RSS

Nanoplatelets, a potential drug delivery vehicle for targeted cancer therapy

Short-lived radioactive isotopes, or radioisotopes, can image tumors or inflict high levels of cellular damage to them.

18 Aug 2026

Early radionuclide therapy delays progression in metastatic prostate cancer

Earlier use of a targeted radionuclide therapy delays metastatic prostate cancer progression when administered as part of a trio of drugs, according to a phase 3 clinical trial led by Weill Cornell Medicine, NewYork-Presbyterian, Memorial Sloan Kettering Cancer Center and investigators at several other institutions worldwide.

6 Aug 2026

Novel PRRT approach shows promise in advanced neuroendocrine tumors

A new type of peptide receptor radionuclide therapy (PRRT) appears to be safe in metastatic neuroendocrine tumor patients who have exhausted conventional treatment options.

31 May 2026

Researchers use tiny glass capillaries to sample living cancer cell parts

A new analytical method could improve how cancer treatments are designed - by allowing scientists to track, for the first time, exactly where inside a living cell a drug accumulates. Researchers from the University of Surrey and King's College London developed the method, which detects trace amounts of metal inside individual living cells and their internal compartments without the need to kill the cells first

17 Apr 2026

Study tests combined targeted radiopharmaceuticals and precision radiation for recurrent prostate cancer

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have opened a clinical trial that will look at whether combining precision radiation with a targeted radioactive therapy drug can help patients with recurrent prostate cancer delay progression, while delaying or avoiding the side effects of long-term hormone therapy.

16 Jan 2026

$New targeted alpha therapy shows promise for patients with radioiodine-refractory thyroid cancer$

New targeted alpha therapy shows promise for patients with radioiodine-refractory thyroid cancer

A new targeted alpha therapy is showing promise for patients whose thyroid cancer no longer responds to radioactive iodine, the standard beta-emitting treatment. In a first-in-human study, investigators found that a single dose of the alpha-emitting radionuclide 211At (astatine) was both well-tolerated and effective, achieving disease control without molecularly targeted drugs.

5 Dec 2025

New radioimmunotherapy approach shows potential to cure HER2-positive breast cancer

A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 (HER2)-positive breast cancer, according to new research published in the November issue of The Journal of Nuclear Medicine.

7 Nov 2025

SNMMI launches AI-powered platform to connect patients with radiopharmaceutical trials

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is proud to announce the launch of the Global Radiopharmaceutical Trial Finder a revolutionary, AI-powered platform designed to help researchers, clinicians and patients instantly discover radiopharmaceutical clinical trials that meet their specific needs.

12 Aug 2025

New radioimmunotherapy approach eliminates cancer stem cells in preclinical models of ovarian cancer

A new radioimmunotherapy approach has been shown to successfully eliminate cancer stem cells (CSCs) in preclinical models of ovarian cancer, outperforming the current gold standard.

1 Aug 2025

Terbium therapy shows promise in fighting lymphoma

Radionuclide therapy with the radioactive element terbium could effectively combat lymphoma. This is demonstrated by promising results from experiments carried out at the Paul Scherrer Institute PSI in collaboration with Inselspital - Bern University Hospital.

2 Jun 2025

Cabozantinib gains FDA approval for treating advanced neuroendocrine tumors

Cabozantinib, an oral tyrosine kinase inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with previously treated advanced neuroendocrine tumors (NETs).

26 Mar 2025

Targeted alpha therapy offers new hope for treating metastatic melanoma

Metastatic melanoma, also known as stage IV melanoma, is a type of skin cancer that spreads to other parts of the body.

12 Mar 2025

Alpha particle therapy offers new hope for neuroendocrine tumors

In a comprehensive Genomic Press Viewpoint (review) article, researchers are shining a spotlight on a revolutionary approach to tackling neuroendocrine tumors (NETs), a rare but increasingly prevalent form of cancer.

4 Mar 2025

Ariceum Therapeutics receives FDA’s Orphan Drug Designation for targeted radionuclide cancer treatment

Ariceum Therapeutics (Ariceum), a private biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to 225Ac-SSO110 (satoreotide) for the treatment of patients with Small Cell Lung Cancer (SCLC).

10 Feb 2025

Researchers develop technology to change protein identity in vivo

Researchers at the RIKEN Cluster for Pioneering Research (CPR) have developed technology that can alter, within the body, the recognized identity of proteins. The innovation, published in Nature Communications on October 2, allowed researchers to target mouse tumors with a protein and then transport that protein out of the body.

3 Oct 2024

Researchers develop stable compound for targeted alpha therapy in prostate cancer

Compounds containing astatine-211 (211At) can be used in targeted radiotherapies for prostate cancer, but deastatination in the body remains a significant hurdle.

3 Sep 2024

Innovations in biomarker detection and personalized medicine for prostate cancer

In a recent comprehensive review published in Cyborg Bionic Systems, researchers led by Keyi Li from the General Hospital of Northern Theater Command in Shenyang, along with international collaborators, detail significant advances in the identification and application of biomarkers for prostate cancer (PCa).

23 Aug 2024

$Osaka University to pioneer world-first clinical trial for refractory prostate cancer with alpha-ray therapy$

Osaka University to pioneer world-first clinical trial for refractory prostate cancer with alpha-ray therapy

A research team at Osaka University will start an investigator-initiated clinical trial for refractory prostate cancer patients after the successful development of a new alpha-ray therapeutic agent ([At-211] PSMA-5) and confirmation of its efficacy in animal models.

27 May 2024

Non-invasive detection and treatment of ovarian cancer with new radiotheranostic system

A new radiotheranostic system has the ability to detect and treat ovarian cancer noninvasively, according to new research published in the April issue of The Journal of Nuclear Medicine.

4 Apr 2024

Urea-powered nanorobots reduce bladder tumors by 90% in mice

The research, which was conducted on mice, demonstrates how these tiny nanomachines are propelled by urea present in urine and precisely target the tumour, attacking it with a radioisotope carried on their surface.

16 Jan 2024